mbg453
Showing 1 - 10 of 10
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
-
Durham, North Carolina
- +8 more
Dec 13, 2022
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Worldwide (Decitabine, PDR001, MBG453)
Active, not recruiting
- Leukemia
- +7 more
- Decitabine
- +3 more
-
Boston, Massachusetts
- +10 more
Jan 19, 2023
Advanced Malignancies Trial in Worldwide (MBG453, PDR001, Decitabine)
Terminated
- Advanced Malignancies
- MBG453
- +2 more
-
Baltimore, Maryland
- +13 more
Sep 20, 2022
Glioblastoma Multiforme Trial in Stanford, Baltimore (MBG453)
Active, not recruiting
- Glioblastoma Multiforme
- MBG453
-
Stanford, California
- +1 more
Nov 22, 2022
Acute Myeloid Leukemia Trial in Worldwide (MBG453, Venetoclax, Azacitidine)
Active, not recruiting
- Acute Myeloid Leukemia
- MBG453
- +2 more
-
Birmingham, Alabama
- +27 more
Jan 20, 2023
MDS Trial in Boston (MBG453)
Not yet recruiting
- Myelodysplastic Syndromes
- MBG453
-
Boston, Massachusetts
- +2 more
Mar 28, 2021
Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)
Recruiting
- Myelodysplastic Syndrome (MDS)
- MBG453
- +3 more
-
Chandler, Arizona
- +22 more
Dec 5, 2022
MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)
Active, not recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
-
Duarte, California
- +46 more
Jan 20, 2023
MDS Trial in Worldwide (MBG453, NIS793, canakinumab)
Recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
-
Duarte, California
- +14 more
Jan 23, 2023
Primary Myelofibrosis, Myelofibrosis, PMF Trial (MBG453, NIS793, Spartalizumab)
Withdrawn
- Primary Myelofibrosis
- +4 more
- MBG453
- +3 more
- (no location specified)
Mar 2, 2021